Merck buys the rights to an experimental Ebola vaccine

Deal comes as other drugmakers are racing to test and scale up production of treatments and preventive vaccines.

Merck on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp’s experimental vaccine meant to prevent infection with the Ebola virus.

Large late-stage trials of the product could begin early next year, Merck said… (read more)